CJC-1295 research guide for Frantzís. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
The quest for CJC-1295 in Frantzís almost always leads to the same conclusion: research peptides are distributed through specialist online vendors, not high-street stores. The core insight for Frantzís researchers: sourcing CJC-1295 hinges on vendor quality evaluation, not geography — and the framework for evaluating that quality is the same regardless of where you are. Separating quality CJC-1295 from the rest of the market comes down to three things: an HPLC chromatogram documenting ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. Use this guide to assess sourcing options methodically — the standards covered in this guide apply whether you are in Frantzís or anywhere else.
How CJC-1295 Works — Mechanisms & Research
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Frantzís studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Source CJC-1295 — Vendor Guide
The most effective path to quality CJC-1295 is engaging research communities before vendor sites — peptide forums track vendor quality over time that are more accurate than commercial vendor claims. When reviewing a CJC-1295 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec confirms the correct peptide, and endotoxin levels are below the threshold for research use. Warning signs in CJC-1295 vendor evaluation: prices significantly below market average, unclear production details, no community presence, and COAs that omit endotoxin testing. Keep lyophilised CJC-1295 at minus 20 degrees Celsius until ready to use; reconstitute only the volume needed for upcoming use and return unused portion to the freezer.
Order CJC-1295 — ships to Frantzís
COA-verified · International tracking · Research grade
CJC-1295 is supplied strictly for research applications and is not approved for human consumption by the FDA or comparable health authorities — all information here is educational. Proper handling of CJC-1295 requires careful sterile procedure — alcohol-swabbed septum, fresh needles, clean working environment — and cold chain maintenance from receipt through use. Verify the endotoxin level in your CJC-1295 batch COA before any protocol involving administration — look for results reported in endotoxin units per mg or mL and compare against acceptable research limits for your application. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is not approved for human use and its risk profile is not equivalent to approved medications.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
